跳至主要内容
临床试验/CTRI/2021/07/034608
CTRI/2021/07/034608进行中(未招募)1 期

An essential need during the COVID pandemic: Hypofractionated adjuvant radiotherapy in resected head and neck cancers - HYPO-ART

one0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
one

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients with resected head and neck squamous cell cancers with clinical/pathological stage III or stage IV and/or with indications of adjuvant radiotherapy post-surgery
  • 2.WHO ECOG Performance Score of 2 or less.
  • 3.Patients 18 to 70 years age
  • 4.Haemoglobin > 10gm/dL, TLC > 4000/mm3 and Platelet count > 100,000/mm3.
  • 5.Normal liver, renal lung and cardiac function.
  • 6.No evidence of a second primary elsewhere in the body.

排除标准

  • 1.Cancers with histology other than squamous cell carcinoma
  • 2.Patients who are medically unfit for surgery or not willing for surgery.
  • 3.Distant metastases (Stage IVC)
  • 4.Patients with history of prior malignancy.
  • 5.Patients having received prior chemotherapy and radiotherapy to the head and neck.
  • 6.Patients having undergone surgery involving primary tumour or lymph nodes (except diagnostic biopsy)
  • 7.Patients with signs of severe ischaemic disease, severe arteriosclerosis, active coronary artery disease, cardiac arrhythmia, congestive cardiac failure, and a history of peripheral neuropathy or cerebral stroke.

研究者

发起方
one

相似试验